TY - JOUR
T1 - Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): Experience from the RESITRA-REIPI cohort
AU - Meije, Y.
AU - Fortún, J.
AU - Len, O.
AU - Aguado, J. M.
AU - Moreno, A.
AU - Cisneros, J. M.
AU - Gurguí, M.
AU - Carratalà, J.
AU - Muñoz, P.
AU - Montejo, M.
AU - Blanes, M.
AU - Bou, G.
AU - Pérez, J. L.
AU - Torre-Cisneros, J.
AU - Ramos, A.
AU - Pahissa, A.
AU - Gavaldà, J.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Background: Cytomegalovirus (CMV)-negative recipients of a graft from a CMV-positive donor (D+/R-) are at high risk of CMV disease. Current preventive strategies include universal prophylaxis (UP) and preemptive therapy (PT). However, the best strategy to prevent CMV disease and achieve better long-term outcomes remains a matter of debate. Methods: We analyzed the incidence of CMV disease and long-term outcomes including graft dysfunction and patient mortality at 5 years after transplantation with both preventive strategies. High-risk (D+/R-) kidney and liver transplant recipients from the RESITRA cohort were included. Results: Of 2410 kidney or liver transplant patients, 195 (8.3%) were D+/R- The final cohort included 58 liver and 102 kidney recipients. UP was given in 92 patients and 68 received PT; 10.9% and 36.8% developed CMV disease, respectively (P < 0.01). The independent risk factors for CMV disease were PT strategy (hazard ratio [HR], 3.30; 95% confidence interval [CI], 1.6-6.9), kidney transplantation (HR, 3.8; 95% CI, 1.4-9.9), and cyclosporine immunosuppression (HR, 2.4; 95% CI, 1.2-4.7). PT strategy was also a risk factor for CMV disease in both liver transplantation (HR, 11.0; 95% CI, 1.2-98.7) and kidney transplantation (HR, 2.7; 95% CI, 1.3-6.0), independently. The development of CMV replication during the first 2 years after transplantation was a risk factor for graft dysfunction at 5 years after transplantation (odds ratio, 3.4; 95% CI, 1.3-9.0). Nevertheless, no significant differences were seen in either graft dysfunction or mortality between the 2 strategies. Conclusions: The study supports the benefit of the UP strategy to prevent CMV disease in D+/R- liver or kidney transplant patients. The development of CMV replication during the first 2 years after transplantation was associated with graft dysfunction at 5 years after transplantation. © 2014 Wiley Periodicals, Inc.163 June 2014 10.1111/tid.12226 Original Article Original articles © 2014 John Wiley & Sons A/S.
AB - Background: Cytomegalovirus (CMV)-negative recipients of a graft from a CMV-positive donor (D+/R-) are at high risk of CMV disease. Current preventive strategies include universal prophylaxis (UP) and preemptive therapy (PT). However, the best strategy to prevent CMV disease and achieve better long-term outcomes remains a matter of debate. Methods: We analyzed the incidence of CMV disease and long-term outcomes including graft dysfunction and patient mortality at 5 years after transplantation with both preventive strategies. High-risk (D+/R-) kidney and liver transplant recipients from the RESITRA cohort were included. Results: Of 2410 kidney or liver transplant patients, 195 (8.3%) were D+/R- The final cohort included 58 liver and 102 kidney recipients. UP was given in 92 patients and 68 received PT; 10.9% and 36.8% developed CMV disease, respectively (P < 0.01). The independent risk factors for CMV disease were PT strategy (hazard ratio [HR], 3.30; 95% confidence interval [CI], 1.6-6.9), kidney transplantation (HR, 3.8; 95% CI, 1.4-9.9), and cyclosporine immunosuppression (HR, 2.4; 95% CI, 1.2-4.7). PT strategy was also a risk factor for CMV disease in both liver transplantation (HR, 11.0; 95% CI, 1.2-98.7) and kidney transplantation (HR, 2.7; 95% CI, 1.3-6.0), independently. The development of CMV replication during the first 2 years after transplantation was a risk factor for graft dysfunction at 5 years after transplantation (odds ratio, 3.4; 95% CI, 1.3-9.0). Nevertheless, no significant differences were seen in either graft dysfunction or mortality between the 2 strategies. Conclusions: The study supports the benefit of the UP strategy to prevent CMV disease in D+/R- liver or kidney transplant patients. The development of CMV replication during the first 2 years after transplantation was associated with graft dysfunction at 5 years after transplantation. © 2014 Wiley Periodicals, Inc.163 June 2014 10.1111/tid.12226 Original Article Original articles © 2014 John Wiley & Sons A/S.
KW - Cytomegalovirus
KW - Graft dysfunction
KW - Preemptive therapy
KW - Transplantation
KW - Universal prophylaxis
U2 - 10.1111/tid.12226
DO - 10.1111/tid.12226
M3 - Article
SN - 1398-2273
VL - 16
SP - 387
EP - 396
JO - Transplant Infectious Disease
JF - Transplant Infectious Disease
IS - 3
ER -